Core Viewpoint - The article highlights the recent completion of nearly 100 million RMB Series A financing by Suzhou Zhongxi Biological Information Co., Ltd. (Zhongxi Bio), aimed at accelerating the development and global promotion of its automated intelligent ecosystem in life sciences [1][5]. Company Overview - Suzhou Zhongxi Biological Information Co., Ltd. was established in 2014 and focuses on automation in life sciences, providing automated equipment and comprehensive solutions for various fields including biopharmaceuticals, clinical diagnostics, public health, food safety, and agricultural breeding [1][3]. - The company is recognized as one of the early enterprises in China to conduct research on liquid handling systems, accumulating extensive R&D experience and technical talent [1]. Business Operations - Zhongxi Bio's main business encompasses automation and solutions in life sciences, biopharmaceuticals, forensics, clinical diagnostics, public health, and food quality and safety [3]. - The company offers high-precision micro-liquid handling platforms, fully automated cup systems, electrophoresis systems, nucleic acid extraction systems, and enzyme-linked detection systems [3]. Financing History - In January 2024, Zhongxi Bio completed a Pre-A+ round of financing led by QM261 Limited, with continued investment from Qiming Venture Partners [4]. - In April 2024, the company secured another Pre-A+ round of financing from Suzhou Sequoia Puxin II Medical Health Industry Investment Partnership, with connections to Sequoia Capital [4]. - The recent Series A financing in July 2025 was led by CITIC Construction Investment, with ongoing investment from Qiming Venture Partners [5].